BofA raised the firm’s price target on Merus to $44 from $38 and keeps a Buy rating on the shares after the company hosted CEO Bill Lundberg to discuss expectations for the company in 2024. The firm continues to be encouraged by petosemtamab’s differentiated profile in second-line and later head and neck squamous cell carcinoma, or HNSCC, given the large unmet need and supporting potential competitive efficacy in first-line use, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MRUS: